drugset / Trial / NCT00329043
Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to learn if the addition of sunitinib malate (SU011248) to hormone based castration is an effective treatment for shrinking or controlling the tumor before having the prostate removed.
Timeline
- Start
- 2006-05-15
- Primary completion
- 2027-12-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Leuprolide | Other / unclassified | — | Intramuscular |
| Subject | Sunitinib | Small molecule | 25 mg | Oral |
| Subject | Sunitinib | Small molecule | 37.5 mg | Oral |